secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2026-02-10T23:59:59+00:00
Accession:  0001171843-26-000721
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience preliminary Q4 revenue $23.7M, adj EBITDA $3.8M, 27% YoY growth
--------------------------------------------------------------------------------

- Preliminary Q4 revenue $23.7M, above guidance midpoint; gross margin 60% at high end of 58-60% range.
- Adjusted EBITDA $3.8M, up 27% YoY, driven by cost reductions and expense management.
- 2026 outlook: year-over-year revenue growth and mid-to high-single-digit adjusted EBITDA growth.
- Strategy focuses on translational science tools, consumables expansion (55% recurring revenue), and operational excellence.
- Full Q4 and FY2025 results to be released March 12, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184326000721/0001171843-26-000721-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184326000721/f8k_020926.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000721

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer